Speed up the access to and uptake of an Mpox vaccine
Awarded
The competition has ended and a winner has been selected.
- Deadline
- Jul 24, 2025Expired
- Award
- Price 20%
Brief
The objective of this call for tender is to strengthen the scientific evidence on the immune response provided by the Modified Vaccinia Ankara virus-Bavarian Nordic (MVA-BN) vaccine, with particular emphasis on the need and optimal timing of booster doses. Therefore, the purpose of this call for tenders is to purchase clinical services for clinical research and/or other equivalent scientific activities to evaluate and compare the immunogenicity of a booster dose of MVA-BN vaccine considering different routes of administration, namely intradermal and subcutaneous injection, and the appropriate timing of the booster dose. The activities under this call are expected to include a Phase II and/or Phase III clinical trial(s). The results of the clinical trial(s) should be able to contribute to the development and refinement of vaccination strategies to be adopted by public health authorities, as well as, provide further evidence for the European Commission and EU Member States to consider when developing relevant policies, e.g. on stockpiling initiatives, and/or the feasibility of dose-sparing strategies for Mpox vaccination during shortages
Statistikk og markedsundersøkelser
Result
- FOLKHALSOMYNDIGHETENWinner
- 1Number of tenders received
- €4,900,000Contract value
Custom Assessment Criteria
Get answers to your bid/no-bid criteria
Set them up once and Cobrief answers them in every tender
Will you bid?
The agent sets up the bid and writes the first draft. Free for 14 days.
Award Criteria
Description
Please consult the procurement documents.
Source
No source found in the documents. Check the weight against the tender documents.
Description
Please consult the procurement documents.
Source
No source found in the documents. Check the weight against the tender documents.
Previous winners
Who are you up against?
The suppliers who have won similar contracts at Health and Digital Executive Agency (HaDEA) , HADEA - Health and Digital Executive Agency
From the notice
The objective of this call for tender is to strengthen the scientific evidence on the immune response provided by the Modified Vaccinia Ankara virus-Bavarian Nordic (MVA-BN) vaccine, with particular emphasis on the need and optimal timing of booster doses. Therefore, the purpose of this call for tenders is to purchase clinical services for clinical research and/or other equivalent scientific activities to evaluate and compare the immunogenicity of a booster dose of MVA-BN vaccine considering different routes of administration, namely intradermal and subcutaneous injection, and the appropriate timing of the booster dose. The activities under this call are expected to include a Phase II and/or Phase III clinical trial(s). The results of the clinical trial(s) should be able to contribute to the development and refinement of vaccination strategies to be adopted by public health authorities, as well as, provide further evidence for the European Commission and EU Member States to consider when developing relevant policies, e.g. on stockpiling initiatives, and/or the feasibility of dose-sparing strategies for Mpox vaccination during shortages
Contact
hadea-procurement@ec.europa.eu- ResultType
- 73000000Main codeResearch and development services and related consultancy services
- 73300000Design and execution of research and development